# Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

> **NCT00649129** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Oxybutynin Chloride ER Tablets 10 mg
- **DRUG:** Ditropan XL® Tablets 10 mg

## Key facts

- **NCT ID:** NCT00649129
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2002-08
- **Final completion:** 2002-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00649129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00649129, "Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00649129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*